Trial Profile
A Phase II study of failure-free survival following treatment with midostaurin in combination with standard chemotherapy in newly diagnosed patients with Core Binding Factor Acute Myeloid Leukaemia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 24 May 2017
Price :
$35
*
At a glance
- Drugs Midostaurin (Primary) ; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms AMLM19
- 19 May 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to Lack of funding/staff/facilities.
- 22 Aug 2012 New trial record